(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Are Saturn's rings made of a lost, shattered moon? New evidence arises for the case - 2Russia accidentally destroys its only way of sending astronauts to space
- 3Revvity says it will exceed 2025 profit forecast range
- 4NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- 5Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- Did Japan’s PM Actually Back the Memecoin Bearing Her Name?
- Munich Security Conference chief defends inviting AfD lawmakers
- Computerized Moderation: Tracking down Equilibrium in the Advanced Age
- 3 Must-Change Settings for iPhone Clients: Safeguard Yourself !
- Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- A definitive Manual for the Over-Ear Earphones
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- Creative Style: 10 Architects Reclassifying the Business
